Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis, Published online: 24 May 2018; doi:10.1038/s41408-018-0086-3Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: Efstathios Kastritis Ioannis V. Kostopoulos Evangelos Terpos Bruno Paiva Despina Fotiou Maria Gavriatopoulou Nikolaos Kanellias Dimitrios C. Ziogas Maria Roussou Magdalini Migkou Evangelos Eleutherakis-Papaiakovou Ioannis P. Trougakos Ourania Tsitsilonis Source Type: research

Myelodysplastic syndromes current treatment algorithm 2018
Myelodysplastic syndromes current treatment algorithm 2018, Published online: 24 May 2018; doi:10.1038/s41408-018-0085-4Myelodysplastic syndromes current treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: David P. Steensma Source Type: research

The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition
The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition, Published online: 24 May 2018; doi:10.1038/s41408-018-0082-7The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: Shira Kahlon Dorin Shreibman Tamar Unger Dina Ben-Yehuda Shlomo Elias Source Type: research

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018, Published online: 23 May 2018; doi:10.1038/s41408-018-0080-9Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 23, 2018 Category: Hematology Authors: Morie A. Gertz Source Type: research

RTK-RAS pathway mutation is enriched in myeloid sarcoma
RTK-RAS pathway mutation is enriched in myeloid sarcoma, Published online: 23 May 2018; doi:10.1038/s41408-018-0083-6RTK-RAS pathway mutation is enriched in myeloid sarcoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 22, 2018 Category: Hematology Authors: Mihong Choi Yoon Kyung Jeon Choong-Hyun Sun Hong-Seok Yun Junshik Hong Dong-Yeop Shin Inho Kim Sung-Soo Yoon Youngil Koh Source Type: research

Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial, Published online: 22 May 2018; doi:10.1038/s41408-018-0084-5Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 22, 2018 Category: Hematology Authors: J érôme Paillassa Thibaut Leguay Xavier Thomas Fran çoise Huguet Marie Audrain V éronique Lheritier Christine Vianey-Saban C écile Acquaviva-Bourdain C écile Pagan Herv é Dombret Norbert Ifrah Nicolas Boissel Mathilde Hunault-Berger Source Type: research

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma, Published online: 11 May 2018; doi:10.1038/s41408-018-0075-6Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 11, 2018 Category: Hematology Authors: Evangelos Terpos Ioannis Ntanasis-Stathopoulos Dimitrios Christoulas Tina Bagratuni Marios Bakogeorgos Maria Gavriatopoulou Evangelos Eleutherakis-Papaiakovou Nikolaos Kanellias Efstathios Kastritis Meletios A. Dimopoulos Source Type: research

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study, Published online: 01 May 2018; doi:10.1038/s41408-018-0071-xDaratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 1, 2018 Category: Hematology Authors: Kenshi Suzuki Meletios A. Dimopoulos Naoki Takezako Shinichiro Okamoto Atsushi Shinagawa Morio Matsumoto Hiroshi Kosugi Sung-Soo Yoon Shang-Yi Huang Xiang Qin Ming Qi Shinsuke Iida Source Type: research

Waldenström macroglobulinemia treatment algorithm 2018
Waldenström macroglobulinemia treatment algorithm 2018Waldenström macroglobulinemia treatment algorithm 2018, Published online: 01 May 2018; doi:10.1038/s41408-018-0076-5Waldenström macroglobulinemia treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 1, 2018 Category: Hematology Authors: Morie A. Gertz Source Type: research

DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line
DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line, Published online: 04 April 2018; doi:10.1038/s41408-018-0072-9DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: David Chen Matthew Christopher Nichole M. Helton Ian Ferguson Timothy J. Ley David H. Spencer Source Type: research

Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome, Published online: 04 April 2018; doi:10.1038/s41408-018-0074-7Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: Hsin-An Hou Cheng-Hong Tsai Chien-Chin Lin Wen-Chien Chou Yuan-Yeh Kuo Chieh-Yu Liu Mei-Hsuan Tseng Yen-Ling Peng Ming-Chih Liu Chia-Wen Liu Xiu-Wen Liao Liang-In Lin Ming Yao Jih-Luh Tang Hwei-Fang Tien Source Type: research

Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome
Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome, Published online: 04 April 2018; doi:10.1038/s41408-018-0073-8Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: Hao Zhao Hao Cai Chen Wang Xu-fei Huang Xin-xin Cao Lu Zhang Dao-bin Zhou Jian Li Source Type: research

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia
miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia, Published online: 21 March 2018; doi:10.1038/s41408-018-0070-ymiR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Rosanna H. E. Krakowsky Alexander A. Wurm Dennis Gerloff Christiane Katzerke Daniela Br äuer-Hartmann Jens-Uwe Hartmann Franziska Wilke Christian Thiede Carsten M üller-Tidow Dietger Niederwieser Gerhard Behre Source Type: research

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients, Published online: 21 March 2018; doi:10.1038/s41408-018-0069-4Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Bei Jia Liru Wang David F. Claxton W Christopher Ehmann Witold B. Rybka Shin Mineishi Syed Rizvi Hiroko Shike Michael Bayerl Todd D. Schell Raymond J. Hohl Hong Zheng Source Type: research

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5, Published online: 21 March 2018; doi:10.1038/s41408-018-0062-yA multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Brian S. White Irena Lanc Julie O ’Neal Harshath Gupta Robert S. Fulton Heather Schmidt Catrina Fronick Edward A. Belter Jr. Mark Fiala Justin King Greg J. Ahmann Mary DeRome Elaine R. Mardis Ravi Vij John F. DiPersio Joan Levy Daniel Auclair Michael H. Source Type: research

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma, Published online: 20 March 2018; doi:10.1038/s41408-018-0066-7The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 20, 2018 Category: Hematology Authors: Shengjian Huang Changying Jiang Hui Zhang Taylor Bell Hui Guo Yang Liu Yixin Yao Dongfeng Zeng Makhdum Ahmed Krystle Nomie Leo Zhang Michael Wang Source Type: research

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms, Published online: 12 March 2018; doi:10.1038/s41408-018-0057-8Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 12, 2018 Category: Hematology Authors: Terra L. Lasho Rangit Vallapureddy Christy M. Finke Abhishek Mangaonkar Naseema Gangat Rhett Ketterling Ayalew Tefferi Mrinal M. Patnaik Source Type: research

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group, Published online: 09 March 2018; doi:10.1038/s41408-018-0059-6Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 9, 2018 Category: Hematology Authors: Eirini Katodritou Evangelos Terpos Sossana Delimpasi Maria Kotsopoulou Eurydiki Michalis Chrysanthi Vadikolia Marie-Christine Kyrtsonis Argiris Symeonidis Nikolaos Giannakoulas Chrissa Vadikolia Michalis Michael Christina Kalpadakis Theodora Gougopoulou C Source Type: research

A systematic classification of death causes in multiple myeloma
A systematic classification of death causes in multiple myeloma, Published online: 08 March 2018; doi:10.1038/s41408-018-0068-5A systematic classification of death causes in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 8, 2018 Category: Hematology Authors: Elias K. Mai Eva-Maria Haas Stephan L ücke Martin L öpprich Christina Kunz Maria Pritsch Petra Knaup-Gregori Marc S. Raab Jana Schlenzka Uta Bertsch Jens Hillengass Hartmut Goldschmidt Source Type: research

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders
Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders, Published online: 07 March 2018; doi:10.1038/s41408-018-0061-zDetailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 7, 2018 Category: Hematology Authors: Julie Schanz Naciye Cevik Christa Fonatsch Friederike Braulke Katayoon Shirneshan Ulrike Bacher Detlef Haase Source Type: research

Momelotinib therapy for myelofibrosis: a 7-year follow-up
Momelotinib therapy for myelofibrosis: a 7-year follow-up, Published online: 07 March 2018; doi:10.1038/s41408-018-0067-6Momelotinib therapy for myelofibrosis: a 7-year follow-up (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 7, 2018 Category: Hematology Authors: Ayalew Tefferi Daniela Barraco Terra L. Lasho Sahrish Shah Kebede H. Begna Aref Al-Kali William J. Hogan Mark R. Litzow Curtis A. Hanson Rhett P. Ketterling Naseema Gangat Animesh Pardanani Source Type: research

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms, Published online: 28 February 2018; doi:10.1038/s41408-018-0048-9Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Valerio De Stefano Alessandra Carobbio Vincenzo Di Lazzaro Paola Guglielmelli Alessandra Iurlo Maria Chiara Finazzi Elisa Rumi Francisco Cervantes Elena Maria Elli Maria Luigia Randi Martin Griesshammer Francesca Palandri Massimiliano Bonifacio Juan-Carlo Source Type: research

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies, Published online: 28 February 2018; doi:10.1038/s41408-018-0065-8Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Praful Ravi Shaji K. Kumar James R. Cerhan Matthew J. Maurer David Dingli Stephen M. Ansell S. Vincent Rajkumar Source Type: research

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era, Published online: 28 February 2018; doi:10.1038/s41408-018-0064-9Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Rebecca L. King Grzegorz S. Nowakowski Thomas E. Witzig David W. Scott Richard F. Little Fangxin Hong Randy D. Gascoyne Brad S. Kahl William R Macon Source Type: research

Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling
Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling, Published online: 26 February 2018; doi:10.1038/s41408-018-0063-xProtease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 26, 2018 Category: Hematology Authors: Xiangke Xin Yunchuan Ding Ying Yang Xing Fu Jianfeng Zhou Chad M. McKee Ruth J. Muschel Robert P. Gale Jane F. Apperley Danmei Xu Source Type: research

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCLCXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL, Published online: 22 February 2018; doi:10.1038/s41408-018-0056-9CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 22, 2018 Category: Hematology Authors: Joo Hyun Kim Won Seog Kim Kyung Ju Ryu Seok Jin Kim Chaehwa Park Source Type: research

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival, Published online: 15 February 2018; doi:10.1038/s41408-018-0058-7CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 15, 2018 Category: Hematology Authors: Natasha Szuber Christy M. Finke Terra L. Lasho Michelle A. Elliott Curtis A. Hanson Animesh Pardanani Ayalew Tefferi Source Type: research

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome, Published online: 15 February 2018; doi:10.1038/s41408-018-0060-0Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 15, 2018 Category: Hematology Authors: Chunyan Gu Carol Holman Ramakrishna Sompallae Xuefang Jing Michael Tomasson Dirk Hose Anja Seckinger Fenghuang Zhan Guido Tricot Hartmut Goldschmidt Ye Yang Siegfried Janz Source Type: research

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma, Published online: 13 February 2018; doi:10.1038/s41408-018-0053-zThe small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 13, 2018 Category: Hematology Authors: Sara Canovas Nunes Martina Manzoni Marco Pizzi Elisa Mandato Marilena Carrino Laura Quotti Tubi Renato Zambello Fausto Adami Andrea Visentin Gregorio Baril à Livio Trentin Sabrina Manni Antonino Neri Gianpietro Semenzato Francesco Piazza Source Type: research

Chronic neutrophilic leukemia: new science and new diagnostic criteria
Chronic neutrophilic leukemia: new science and new diagnostic criteria, Published online: 13 February 2018; doi:10.1038/s41408-018-0049-8Chronic neutrophilic leukemia: new science and new diagnostic criteria (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 13, 2018 Category: Hematology Authors: Natasha Szuber Ayalew Tefferi Source Type: research

Rac1 is a novel therapeutic target in mantle cell lymphoma
Rac1 is a novel therapeutic target in mantle cell lymphoma, Published online: 12 February 2018; doi:10.1038/s41408-018-0052-0Rac1 is a novel therapeutic target in mantle cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Tian Tian Chengfeng Bi Ashley L. Hein Xuan Zhang Cheng Wang Songfei Shen Ji Yuan Timothy C. Greiner Charles Enke Julie Vose Ying Yan Kai Fu Source Type: research

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts, Published online: 12 February 2018; doi:10.1038/s41408-018-0051-1Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Abhishek A. Mangaonkar Terra L. Lasho Christy M. Finke Naseema Gangat Aref Al-Kali Michelle A. Elliott Kebede H. Begna Hassan Alkhateeb Alexandra P. Wolanskyj-Spinner Curtis A. Hanson Rhett P. Ketterling William J. Hogan Animesh Pardanani Mark R. Litzow A Source Type: research

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignanciesFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies, Published online: 12 February 2018; doi:10.1038/s41408-018-0055-xFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Arnon P. Kater Sanne H. Tonino Marjolein Spiering Martine E D Chamuleau Roberto Liu Adeboye Henry Adewoye Jie Gao Lyndah Dreiling Yan Xin Jeanette K. Doorduijn Marie Jos é Kersten Source Type: research

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion, Published online: 09 February 2018; doi:10.1038/s41408-018-0054-yThe 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 9, 2018 Category: Hematology Authors: Tiziano Barbui J ürgen Thiele Heinz Gisslinger Hans Michael Kvasnicka Alessandro M. Vannucchi Paola Guglielmelli Attilio Orazi Ayalew Tefferi Source Type: research

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers, Published online: 29 January 2018; doi:10.1038/s41408-018-0050-2Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 29, 2018 Category: Hematology Authors: Alissa Visram Christopher Bredeson David Allan Mitchell Sabloff Lothar Huebsch Jason Tay Natasha Kekre Sheryl McDiarmid Ranjeeta Mallick Alan Tinmouth Lisa Martin Linda Hamelin Dawn Maze Source Type: research

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor
The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor, Published online: 26 January 2018; doi:10.1038/bcj.2017.102The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 26, 2018 Category: Hematology Authors: R Wu A Sattarzadeh B Rutgers A Diepstra A van den Berg L Visser Source Type: research

Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma, Published online: 25 January 2018; doi:10.1038/s41408-017-0043-6Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 25, 2018 Category: Hematology Authors: Kazuna Tanba Yoshiaki Chinen Hitoji Uchiyama Nobuhiko Uoshima Kazuho Shimura Shinichi Fuchida Miki Kiyota Mitsushige Nakao Yuji Shimura Tsutomu Kobayashi Shigeo Horiike Katsuya Wada Chihiro Shimazaki Hiroto Kaneko Yutaka Kobayashi Masafumi Taniwaki Junya Source Type: research

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition
Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition, Published online: 24 January 2018; doi:10.1038/s41408-017-0039-2Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 24, 2018 Category: Hematology Authors: Gabriela Galicia-V ázquez Sarah Smith Raquel Aloyz Source Type: research

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental, Published online: 22 January 2018; doi:10.1038/s41408-017-0045-4EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 22, 2018 Category: Hematology Authors: Mrinal M. Patnaik Rangit Vallapureddy Terra L. Lasho Katherine P. Hoversten Christy M. Finke Rhett Ketterling Curtis Hanson Naseema Gangat Ayalew Tefferi Source Type: research

Current applications of multiparameter flow cytometry in plasma cell disorders
Current applications of multiparameter flow cytometry in plasma cell disorders, Published online: 19 January 2018; doi:10.1038/bcj.2017.101Current applications of multiparameter flow cytometry in plasma cell disorders (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 19, 2018 Category: Hematology Authors: T Jelinek R Bezdekova M Zatopkova L Burgos M Simicek T Sevcikova B Paiva R Hajek Source Type: research

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia, Published online: 19 January 2018; doi:10.1038/s41408-017-0036-5SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 19, 2018 Category: Hematology Authors: Patricia Johansson Ludger Klein-Hitpass Axel Choidas Peter Habenberger Bijan Mahboubi Baek Kim Anke Bergmann Ren é Scholtysik Martina Brauser Anna Lollies Reiner Siebert Thorsten Zenz Ulrich D ührsen Ralf K üppers Jan D ürig Source Type: research

Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways, Published online: 17 January 2018; doi:10.1038/s41408-017-0047-2Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 17, 2018 Category: Hematology Authors: Mathijs Willemsen Myrurgia Abdul Hamid Bjorn Winkens Axel zur Hausen Source Type: research

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia, Published online: 16 January 2018; doi:10.1038/s41408-017-0044-5Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 16, 2018 Category: Hematology Authors: Pablo Mozas Alfredo Rivas-Delgado Tycho Baumann Neus Villamor Valent ín Ortiz-Maldonado Marta Aymerich Dolors Costa Alba Navarro Eva Gin é Armando L ópez-Guillermo Emili Montserrat Julio Delgado Source Type: research

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data, Published online: 16 January 2018; doi:10.1038/s41408-017-0038-3Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 16, 2018 Category: Hematology Authors: Arianna Ghirardi Alessandra Carobbio Arianna Masciulli Tiziano Barbui Source Type: research

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response, Published online: 15 January 2018; doi:10.1038/s41408-017-0029-4Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 15, 2018 Category: Hematology Authors: Xueping Luo Zefeng Xu Bing Li Tiejun Qin Peihong Zhang Hongli Zhang Liwei Fang Lijuan Pan Naibo Hu Shiqiang Qu Yue Zhang Gang Huang Robert Peter Gale Zhijian Xiao Source Type: research

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?, Published online: 12 January 2018; doi:10.1038/s41408-017-0046-3Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2018 Category: Hematology Authors: Maura Nicolosi Mythri Mudireddy Naseema Gangat Animesh Pardanani Curtis A. Hanson Rhett P. Ketterling Ayalew Tefferi Source Type: research

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Pathogenesis of bone disease in multiple myeloma: from bench to bedside, Published online: 12 January 2018; doi:10.1038/s41408-017-0037-4Pathogenesis of bone disease in multiple myeloma: from bench to bedside (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2018 Category: Hematology Authors: Evangelos Terpos Ioannis Ntanasis-Stathopoulos Maria Gavriatopoulou Meletios A. Dimopoulos Source Type: research

Polycythemia vera treatment algorithm 2018
Polycythemia vera treatment algorithm 2018, Published online: 10 January 2018; doi:10.1038/s41408-017-0042-7Polycythemia vera treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Ayalew Tefferi Alessandro M. Vannucchi Tiziano Barbui Source Type: research

Essential thrombocythemia treatment algorithm 2018
Essential thrombocythemia treatment algorithm 2018, Published online: 10 January 2018; doi:10.1038/s41408-017-0041-8Essential thrombocythemia treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Ayalew Tefferi Alessandro M. Vannucchi Tiziano Barbui Source Type: research

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1, Published online: 10 January 2018; doi:10.1038/s41408-017-0040-9Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Caner Saygin Cassandra Hirsch Bartlomiej Przychodzen Mikkael A. Sekeres Betty K. Hamilton Matt Kalaycio Hetty E. Carraway Aaron T. Gerds Sudipto Mukherjee Aziz Nazha Ronald Sobecks Christopher Goebel Donna Abounader Jaroslaw P. Maciejewski Anjali S. Advan Source Type: research